Merck/Rosetta Scales Up Merck's Genomics Effort, Merger Comfort Level?
Executive Summary
Merck's $620 mil. acquisition offer for Rosetta Inpharmatics will scale up Merck's genomics research efforts - and may also scale up its tolerance for mergers and acquisitions.
You may also be interested in...
Weeding Out Pipeline “Dogs” Early Can Be As Valuable As A Blockbuster
Eliminating "bad" compounds from the pipeline early in the development process can generate as much value as picking a blockbuster, McKinsey Partner Rodney Zemmel suggested Sept. 26
Weeding Out Pipeline “Dogs” Early Can Be As Valuable As A Blockbuster
Eliminating "bad" compounds from the pipeline early in the development process can generate as much value as picking a blockbuster, McKinsey Partner Rodney Zemmel suggested Sept. 26
Democracy In Action: Biotech Access To R&D Tools Spurs Licensing Deals
Drug licensing opportunities have increased 60% over the past five years, due in part to a "democratization" of technology previously available only to large pharma, Merck Senior VP-Worldwide Licensing & External Research Mervyn Turner, PhD, said